Robert Whalen
Plus aucun poste en cours
Profil
Robert Whalen was the founder of Altravax, Inc. which was founded in 2009, where he held the title of Chief Scientific Officer from 2009 to 2013.
He was also a Director-Infectious Diseases at Maxygen, Inc. Mr. Whalen received his graduate degree from Harvard University in 1974 and his undergraduate degree from The Pennsylvania State University in 1970.
Anciens postes connus de Robert Whalen
| Sociétés | Poste | Fin |
|---|---|---|
Maxygen, Inc.
 Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Corporate Officer/Principal | - |
Altravax, Inc.
 Altravax, Inc. Pharmaceuticals: MajorHealth Technology Altravax, Inc. discovers and develops new vaccines to fight infectious diseases. The firm’s proprietary technologies offer unique opportunities to create novel vaccine or improve currently available alternatives to fill unmet medical needs. It provides contract services. It has a robust pipeline of candidates at various stages of development. The company was founded by Sean X. Du and Robert Whalen in 2009 and is headquartered in Sunnyvale, CA. | Fondateur | - |
Formation de Robert Whalen
| Harvard University | Graduate Degree |
| The Pennsylvania State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Altravax, Inc.
Altravax, Inc. Pharmaceuticals: MajorHealth Technology Altravax, Inc. discovers and develops new vaccines to fight infectious diseases. The firm’s proprietary technologies offer unique opportunities to create novel vaccine or improve currently available alternatives to fill unmet medical needs. It provides contract services. It has a robust pipeline of candidates at various stages of development. The company was founded by Sean X. Du and Robert Whalen in 2009 and is headquartered in Sunnyvale, CA. | Health Technology |
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Commercial Services |
